Clinical Trial Update: Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study of cetuximab as induction treatment in head and neck squamous cell carcinoma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Head and Neck Neoplasm | Phase 2 | Status: COMPLETED